 |
|
Combined Treatment With Sertraline and Liothyronine in Major DepressionA Randomized, Double-blind, Placebo-Controlled Trial
Rena Cooper-Kazaz, MD;
Jeffrey T. Apter, MD;
Revital Cohen, MA;
Leonid Karagichev, MD;
Said Muhammed-Moussa, MD;
Daniel Grupper, MD;
Taly Drori, MD;
Michael E. Newman, PhD;
Harold A. Sackeim, PhD;
Benjamin Glaser, MD;
Bernard Lerer, MD
Arch Gen Psychiatry. 2007;64(6):679-688.
Background Antidepressant treatments that achieve a higher remission rate than those currently available are urgently needed. The thyroid hormone triiodothyronine may potentiate antidepressant effects.
Objective To determine the antidepressant efficacy and safety of liothyronine sodium (triiodothyronine) when administered concurrently with the selective serotonin reuptake inhibitor sertraline hydrochloride to patients with major depressive disorder.
Design Double-blind, randomized, 8-week, placebo-controlled trial.
Setting Outpatient referral centers.
Patients A total of 124 adult outpatients meeting unmodified DSM-IV criteria for major depressive disorder without psychotic features.
Interventions Patients were randomized to receive sertraline hydrochloride (50 mg/d for 1 week; 100 mg/d thereafter) plus liothyronine sodium (20-25 µg/d for 1 week; 40-50 µg/d thereafter) or sertraline plus placebo for 8 weeks.
Main Outcome Measures The primary outcome measure was categorical response to treatment ( 50% decrease in scores on the 21-item Hamilton Rating Scale for Depression from baseline to study end point). Remission rate (final Hamilton Rating Scale for Depression score,  6) was a secondary outcome measure.
Results Intent-to-treat Hamilton Rating Scale for Depression response rates were 70% and 50% in the sertraline-liothyronine and sertraline-placebo groups, respectively (P = .02; odds ratio, 2.93; 95% confidence interval, 1.23-7.35); remission rates were 58% with sertraline-liothyronine and 38% with sertraline-placebo (P = .02; odds ratio, 2.69; 95% confidence interval, 1.16-6.49). Baseline T3 values were lower in patients treated with sertraline-liothyronine who had remissions than in those without remissions (t48 = 3.36; P<.002). Among patients treated with sertraline-liothyronine, remission was associated with a significant decrease in serum thyrotropin values (F1,73 = 4.00; P<.05). There were no significant effects of liothyronine supplementation on frequency of adverse effects.
Conclusions These results demonstrate enhancement of the antidepressant effect of sertraline by concurrent treatment with liothyronine without a significant increase in adverse effects. The antidepressant effect of liothyronine may be directly linked to thyroid function.
Trial Registration clinicaltrials.gov Identifier: NCT00158990
Author Affiliations: Biological Psychiatry Laboratory, Department of Psychiatry (Drs Cooper-Kazaz, Karagichev, Muhammed-Moussa, Drori, Newman, and Lerer and Ms Cohen), and Endocrinology and Metabolism Service, Department of Internal Medicine (Dr Glaser), Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Global Medical Institutes, Princeton, NJ (Dr Apter); Be’er Ya’akov Mental Health Center, Be’er Ya’akov, Israel (Dr Grupper); and Department of Biological Psychiatry, New York State Psychiatric Institute, New York (Dr Sackeim).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
STAR*D: a summary and UK perspective
Deakin and O'Loughlin
J Psychopharmacol 2009;23:605-612.
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders
Focus 2008;6:379-400.
ABSTRACT
| FULL TEXT
Major Depressive Disorder
Belmaker and Agam
NEJM 2008;358:55-68.
FULL TEXT
|
